Status:
UNKNOWN
MIBG Scintigraphy as a Tool for Selecting Patients Requiring Implantable Cardioverter Defibrillator (ICD)
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Heart Failure
Sudden Death
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of the study is to assess the cardiac innervation in patients with heart failure to better select candidates for an implantable cardioverter defibrillator. Cardiac innervation will be assessed...
Detailed Description
The survival benefit provided by implantable cardioverter defibrillator (ICD) for primary prevention of sudden cardiac death in heart failure compared to medical treatment alone is well established. F...
Eligibility Criteria
Inclusion
- Indication for ICD in primary prevention according to European Society of Cardiology guidelines
Exclusion
- Secondary prevention indication of ICD
- Acute coronary syndrome within the last 40 days
- Revascularization procedure (bypass or percutaneous coronary angioplasty) performed within the last 3 months of planned
- Pregnancy or lactating female
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2018
Estimated Enrollment :
330 Patients enrolled
Trial Details
Trial ID
NCT01185756
Start Date
September 1 2010
End Date
January 1 2018
Last Update
January 11 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupe Hospitalier Bichat - Claude Bernard
Paris, Île-de-France Region, France, 75018